Inhibrx Biosciences, Inc.
INBX
$89.39
$0.290.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -- | 1,200.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -- | 1,200.00% | -- |
| Cost of Revenue | -31.62% | -24.03% | -26.63% | -67.08% | -42.25% |
| Gross Profit | 31.62% | 23.80% | 26.63% | 68.95% | 42.25% |
| SG&A Expenses | -5.21% | -66.54% | -33.24% | -93.12% | -39.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.91% | -38.19% | -27.75% | -82.18% | -41.89% |
| Operating Income | 27.91% | 38.06% | 27.75% | 82.98% | 41.89% |
| Income Before Tax | 22.79% | 31.40% | 19.62% | -101.54% | 44.97% |
| Income Tax Expenses | -- | -- | -- | 0.00% | -- |
| Earnings from Continuing Operations | 22.79% | 31.40% | 19.62% | -101.54% | 44.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.79% | 31.40% | 19.62% | -101.54% | 44.97% |
| EBIT | 27.91% | 38.06% | 27.75% | 82.98% | 41.89% |
| EBITDA | 28.03% | 38.34% | 27.82% | 83.34% | 42.52% |
| EPS Basic | 23.37% | 31.69% | 19.68% | -101.46% | 51.48% |
| Normalized Basic EPS | 23.37% | 31.69% | 19.68% | 83.44% | 51.48% |
| EPS Diluted | 23.37% | 31.73% | 19.72% | -101.48% | 51.48% |
| Normalized Diluted EPS | 23.37% | 31.69% | 19.68% | 83.22% | 51.48% |
| Average Basic Shares Outstanding | 0.76% | 0.42% | 0.06% | 5.81% | 13.41% |
| Average Diluted Shares Outstanding | 0.76% | 0.42% | 0.06% | 4.46% | 13.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |